Marine pharmacology in 2003-4: marine compounds with anthelmintic antibacterial, anticoagulant, antifungal, anti-inflammatory, antimalarial, antiplatelet, antiprotozoal, antituberculosis, and antiviral activities; affecting the cardiovascular, immune and nervous systems, and other miscellaneous mechanisms of action.
The current marine pharmacology review that covers the peer-reviewed literature during 2003 and 2004 is a sequel to the authors' 1998-2002 reviews, and highlights the preclinical pharmacology of 166 marine chemicals derived from a diverse group of marine animals, algae, fungi and bacteria. Anthelmintic, antibacterial, anticoagulant, antifungal, antimalarial, antiplatelet, antiprotozoal, antituberculosis or antiviral activities were reported for 67 marine chemicals. Additionally 45 marine compounds were shown to have significant effects on the cardiovascular, immune and nervous system as well as possessing anti-inflammatory effects. Finally, 54 marine compounds were reported to act on a variety of molecular targets and thus may potentially contribute to several pharmacological classes. Thus, during 2003-2004, research on the pharmacology of marine natural products which involved investigators from Argentina, Australia, Brazil, Belgium, Canada, China, France, Germany, India, Indonesia, Israel, Italy, Japan, Mexico, Morocco, the Netherlands, New Zealand, Norway, Panama, the Philippines, Portugal, Russia, Slovenia, South Korea, Spain, Thailand, Turkey, United Kingdom, and the United States, contributed numerous chemical leads for the continued global search for novel therapeutic agents with broad spectrum activity.
Mayer
Alejandro M S
AM
Department of Pharmacology, Chicago College of Osteopathic Medicine, Midwestern University, 555 31st Street, Downers Grove, Illinois 60515, USA. amayer@midwestern.edu
Rodríguez
Abimael D
AD
Berlinck
Roberto G S
RG
Hamann
Mark T
MT
D000818:Animals; D000871:Anthelmintics / Q000494:pharmacology; D000900:Anti-Bacterial Agents / Q000494:pharmacology; D000893:Anti-Inflammatory Agents / Q000494:pharmacology; D000925:Anticoagulants / Q000494:pharmacology; D000962:Antimalarials / Q000494:pharmacology; D000981:Antiprotozoal Agents / Q000494:pharmacology; D000995:Antitubercular Agents / Q000494:pharmacology; D000998:Antiviral Agents / Q000494:pharmacology; D001688:Biological Products / Q000494:pharmacology*; D002319:Cardiovascular System / Q000187:drug effects; D006801:Humans; D007107:Immune System / Q000187:drug effects; D008386:Marine Biology; D009420:Nervous System / Q000187:drug effects; D010975:Platelet Aggregation Inhibitors / Q000494:pharmacology
D000871:Anthelmintics; D000900:Anti-Bacterial Agents; D000893:Anti-Inflammatory Agents; D000925:Anticoagulants; D000962:Antimalarials; D000981:Antiprotozoal Agents; D000995:Antitubercular Agents; D000998:Antiviral Agents; D001688:Biological Products; D010975:Platelet Aggregation Inhibitors